Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-10-25
DOI
10.1016/j.annonc.2022.10.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
- (2022) Luis A Diaz et al. LANCET ONCOLOGY
- Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study
- (2022) P. Osterlund et al. ESMO Open
- Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases.
- (2022) Nuh N. Rahbari et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk factors for local tumor progression after RFA of pulmonary metastases: a matched case-control study
- (2021) Arash Najafi et al. EUROPEAN RADIOLOGY
- PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
- (2021) Takayuki Yoshino et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
- (2021) François Quénet et al. LANCET ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial
- (2021) Yukihide Kanemitsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
- (2021) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial
- (2021) Tadamichi Denda et al. EUROPEAN JOURNAL OF CANCER
- Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
- (2021) Dominik Paul Modest et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer
- (2021) Erika Martinelli et al. JAMA Oncology
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
- (2020) John A Bridgewater et al. LANCET ONCOLOGY
- Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
- (2020) Chiara Cremolini et al. LANCET ONCOLOGY
- Is Primary Tumor Excision and Specific Metastases Sites Resection Associated With Improved Survival in Stage Ⅳ Colorectal Cancer? Results From SEER Database Analysis
- (2020) Chenghao Yi et al. AMERICAN SURGEON
- Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
- (2020) G. Argiles et al. ANNALS OF ONCOLOGY
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- (2020) M.E. Lacouture et al. ANNALS OF ONCOLOGY
- Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization
- (2019) Marta Schirripa et al. CLINICAL CANCER RESEARCH
- ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
- (2019) C Marchiò et al. ANNALS OF ONCOLOGY
- Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer
- (2019) Filippo Pietrantonio et al. JAMA Oncology
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- (2019) Scott Kopetz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) N Stjepanovic et al. ANNALS OF ONCOLOGY
- FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
- (2019) Dominik P. Modest et al. JOURNAL OF CLINICAL ONCOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study
- (2018) J B Bachet et al. ANNALS OF ONCOLOGY
- European cancer mortality predictions for the year 2018 with focus on colorectal cancer
- (2018) M Malvezzi et al. ANNALS OF ONCOLOGY
- Pulmonary Thermal Ablation Enables Long Chemotherapy-Free Survival in Metastatic Colorectal Cancer Patients
- (2018) Mariane Fonck et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Microwave Ablation in the Management of Colorectal Cancer Pulmonary Metastases
- (2018) I. Kurilova et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Does the Site of the Primary Affect Outcomes When Ablating Colorectal Liver Metastases with Radiofrequency Ablation?
- (2018) Yangkui Gu et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies
- (2018) Peter Gibbs et al. Clinical Colorectal Cancer
- Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review
- (2018) J. Kobiela et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer—central evaluation of FIRE-3
- (2018) D.P. Modest et al. EUROPEAN JOURNAL OF CANCER
- Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
- (2018) Jianming Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)
- (2018) Thomas Aparicio et al. JOURNAL OF CLINICAL ONCOLOGY
- Percutaneous Microwave versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control
- (2018) Waleed Shady et al. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
- (2018) J Mateo et al. ANNALS OF ONCOLOGY
- Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973)
- (2018) Diane Goéré et al. BMC CANCER
- Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
- (2018) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
- (2018) Chiara Cremolini et al. JAMA Oncology
- Geriatric factors and outcomes in metastatic colorectal cancer
- (2017) Demetris Papamichael et al. EUROPEAN JOURNAL OF CANCER
- Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma
- (2017) Fernando Rivera et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Efficacy of Radioembolization with166Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study
- (2017) Jip F. Prince et al. JOURNAL OF NUCLEAR MEDICINE
- Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
- (2017) Theo Ruers et al. JNCI-Journal of the National Cancer Institute
- ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
- (2017) Filippo Pietrantonio et al. JNCI-Journal of the National Cancer Institute
- First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
- (2017) Harpreet S Wasan et al. LANCET ONCOLOGY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: A systematic review
- (2017) Olaguoke Akinwande et al. SURGICAL ONCOLOGY-OXFORD
- Radiofrequency ablation compared to surgical resection for curative treatment of patients with colorectal liver metastases – a meta-analysis
- (2017) Martinus J. van Amerongen et al. HPB
- Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases
- (2017) Waleed Shady et al. Oncotarget
- Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
- (2017) Theo Ruers et al. JNCI-Journal of the National Cancer Institute
- ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
- (2017) Filippo Pietrantonio et al. JNCI-Journal of the National Cancer Institute
- Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer
- (2017) Sabine Tejpar et al. JAMA Oncology
- Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer
- (2017) Giammaria Fiorentini et al. World Journal of Gastrointestinal Oncology
- 501OCALGB/SWOG 80405: PHASE III TRIAL OF IRINOTECAN/5-FU/LEUCOVORIN (FOLFIRI) OR OXALIPLATIN/5-FU/LEUCOVORIN (MFOLFOX6) WITH BEVACIZUMAB (BV) OR CETUXIMAB (CET) FOR PATIENTS (PTS) WITH EXPANDED RAS ANALYSES UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM (MCRC)
- (2017) H. Lenz et al. ANNALS OF ONCOLOGY
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- PARAGON II – A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer
- (2016) R.P. Jones et al. EJSO
- Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy
- (2016) Kamran A. Ahmed et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
- (2016) Guy A. van Hazel et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
- (2016) Sebastian Stintzing et al. LANCET ONCOLOGY
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes—A 10-year Experience at a Single Center
- (2016) Waleed Shady et al. RADIOLOGY
- Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV
- (2015) F. A. Lévi et al. ANNALS OF ONCOLOGY
- Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
- (2015) D. Koeberle et al. ANNALS OF ONCOLOGY
- Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases
- (2015) T. de Baère et al. ANNALS OF ONCOLOGY
- Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis
- (2015) Robert C. G. Martin et al. CANCER
- Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus
- (2015) René Adam et al. CANCER TREATMENT REVIEWS
- Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
- (2015) M. Peeters et al. CLINICAL CANCER RESEARCH
- Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials
- (2015) Matthieu Faron et al. EUROPEAN JOURNAL OF CANCER
- FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
- (2015) C. Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
- (2015) Michael S. Binkley et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- (2015) Ryan B. Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluating Cryoablation of Metastatic Lung Tumors in Patients—Safety and Efficacy The ECLIPSE Trial—Interim Analysis at 1 Year
- (2015) Thierry de Baere et al. Journal of Thoracic Oncology
- Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
- (2015) Lieke H J Simkens et al. LANCET
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
- (2015) Susanna Hegewisch-Becker et al. LANCET ONCOLOGY
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Jin Li et al. LANCET ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope
- (2015) F. Pietrantonio et al. ONCOLOGIST
- Primary Tumor Resection Is Associated with Improved Survival in Stage IV Colorectal Cancer: An Instrumental Variable Analysis
- (2015) Hong Xu et al. Scientific Reports
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
- (2014) J. Y. Douillard et al. ANNALS OF ONCOLOGY
- Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial
- (2014) T. Gruenberger et al. ANNALS OF ONCOLOGY
- Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013
- (2014) D. Papamichael et al. ANNALS OF ONCOLOGY
- Comparison of Complete Pathologic Response and Hepatic Injuries Between Hepatic Arterial Infusion and Systemic Administration of Oxaliplatin in Patients with Colorectal Liver Metastases
- (2014) Marc Antoine Allard et al. ANNALS OF SURGICAL ONCOLOGY
- Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983
- (2014) E. Tanis et al. EUROPEAN JOURNAL OF CANCER
- Shifting sands: adapting the multidisciplinary team model to technological and organizational innovations in cancer care
- (2014) Joan Prades et al. Future Oncology
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial
- (2014) John Primrose et al. LANCET ONCOLOGY
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Ablation and Resection (CARe) as an Effective Parenchymal Sparing Treatment for Extensive Colorectal Liver Metastases
- (2014) Serge Evrard et al. PLoS One
- Decision-making in Colorectal Cancer Tumor Board meetings: Results of a prospective observational assessment
- (2014) S. Shah et al. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
- Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
- (2013) W. Schmiegel et al. ANNALS OF ONCOLOGY
- What to choose as radical local treatment for lung metastases from colo-rectal cancer: Surgery or radiofrequency ablation?
- (2013) Roel C.J. Schlijper et al. CANCER TREATMENT REVIEWS
- Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update
- (2013) M.J. Duffy et al. INTERNATIONAL JOURNAL OF CANCER
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
- (2013) Bernard Nordlinger et al. LANCET ONCOLOGY
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
- (2013) David Cunningham et al. LANCET ONCOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung
- (2012) Dongryul Oh et al. ACTA ONCOLOGICA
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
- (2012) H. J. Schmoll et al. ANNALS OF ONCOLOGY
- “Watchful waiting” for metastatic colorectal cancer, antediluvian or an option to be considered again?
- (2012) Timothy J PRICE et al. Asia-Pacific Journal of Clinical Oncology
- Effect of specialist decision-making on treatment strategies for colorectal liver metastases
- (2012) R. P. Jones et al. BRITISH JOURNAL OF SURGERY
- Survival after Radiofrequency Ablation in 122 Patients with Inoperable Colorectal Lung Metastases
- (2012) Alice Gillams et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Survival Differences in Patients With Metastatic Colorectal Cancer and With Single Site Metastatic Disease at Initial Presentation: Results From South Australian Clinical Registry for Advanced Colorectal Cancer
- (2012) Muhammad A. Khattak et al. Clinical Colorectal Cancer
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study
- (2012) Maarten LJ Smits et al. LANCET ONCOLOGY
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Stereotactic body radiotherapy for oligometastases
- (2012) Alison C Tree et al. LANCET ONCOLOGY
- The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus
- (2012) R. Adam et al. ONCOLOGIST
- Complications After 1000 Lung Radiofrequency Ablation Sessions in 420 Patients: A Single Center’s Experiences
- (2011) Masataka Kashima et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- CT-guided Radiofrequency Ablation as a Salvage Treatment of Colorectal Cancer Hepatic Metastases Developing after Hepatectomy
- (2011) Constantinos T. Sofocleous et al. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Management of Peritoneal Carcinomatosis From Colorectal Cancer
- (2010) Eddy Cotte et al. CANCER JOURNAL
- Intra-Arterial Hepatic Chemotherapy: A Comparison of Percutaneous Versus Surgical Implantation of Port-Catheters
- (2010) F. Deschamps et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy
- (2010) Alain Hendlisz et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
- (2010) Niall C. Tebbutt et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnostic Imaging of Colorectal Liver Metastases with CT, MR Imaging, FDG PET, and/or FDG PET/CT: A Meta-Analysis of Prospective Studies Including Patients Who Have Not Previously Undergone Treatment
- (2010) Maarten Christian Niekel et al. RADIOLOGY
- A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin
- (2009) Christopher Cao et al. ANNALS OF SURGICAL ONCOLOGY
- Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
- (2009) Benoist Chibaudel et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer
- (2009) Sandra L. Wong et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
- (2008) Jim Cassidy et al. JOURNAL OF CLINICAL ONCOLOGY
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- (2008) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin
- (2008) Dominique Elias et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
- (2008) Bernard Nordlinger et al. LANCET
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now